Why Is ALUMIS INC EQUITY (ALMS) Stock Down Today?

ALMS stock fell 7.85% to $25.37 in afternoon trading as the company released topline results from its ONWARD3 long-term extension study. The data showed 54% of patients achieved complete skin clearance after 48 weeks of treatment with envudeucitinib. However, the market reacted negatively, likely due to unmet expectations or broader concerns about the company's financial health and growth trajectory.

What Happened

Alumis announced the results of its ONWARD3 long-term extension study, a key development for its psoriasis treatment. The study showed 54% of patients reached complete skin clearance after 48 weeks of continuous treatment with envudeucitinib. The company filed an 8-K with the SEC on August 10, disclosing the results and related financial statements. The data was reported by multiple outlets, including Benzinga, which highlighted the skin clearance rates and the company's ongoing clinical progress. Despite positive clinical outcomes, the stock price declined sharply, reflecting investor skepticism or a reassessment of the company's potential.

What The Data Shows

Alumis has a market capitalization of $3.5 billion but remains unprofitable with a trailing twelve-month EPS of -2.31. Revenue has declined by 51.7% over the same period. The stock has traded between $3.76 and $31.35 over the past 52 weeks. Recent insider transactions show three senior executives, Chief Development Officer Bradley Mark Christopher, Chief Scientific Officer David M Goldstein, and Chief Medical Officer Jorn Drappa, selling shares on August 3. Over the past 90 days, insiders have sold a total of $534,000 worth of stock with no buy activity reported.

What To Watch

Alumis has no upcoming earnings date listed. Investors should monitor coverage breadth and analyst commentary for further insights into the market's reaction to the ONWARD3 study results and the company's long-term prospects.